ImmunoGenix: Next-Gen Recombinant Immunoglobulin Therapy

ImmunoGenix: Next-Gen Blood Immunity

Recombinant Immunoglobulin Therapy for the Future of Healthcare

The Problem: The Fragility of Blood Defense

The human blood immune system relies heavily on immunoglobulins (mostly IgG) to fight infection. Currently, millions suffer from Primary Immunodeficiency Diseases (PID) and autoimmune disorders. The existing standard of care—plasma-derived IVIG—faces critical supply shortages, high production costs, and significant side effects due to its biological origin.

Current Market Pain Points

High Patient Load: PID impacts 1 in 10,000–50,000 people globally.

Cost Prohibitive: Annual treatment costs exceed $50,000 per patient.

Supply Chain Risk: 73% of the market relies on limited plasma donations.

Demand Surge: 9.3% CAGR in demand is outpacing biological supply capabilities.

The Solution: Recombinant IgG Therapy

Our proprietary recombinant SCIG (Subcutaneous Immunoglobulin) technology eliminates plasma dependency. By engineering a hyperimmune variant, we deliver faster onset and reduced dosing frequency by 50%. This scalable manufacturing process ensures supply security for critical deficiencies.

Market Opportunity (2026-2034)

The global immunoglobulin market is projected to grow at a 7.2% CAGR, reaching $28.7 Billion by 2034. The SCIG delivery segment is growing even faster at 9.1%, driven by patient preference for home-based care.

Market Segmentation Focus

IgG antibodies are the dominant segment, representing 69.4% of the market. Our recombinant solution targets this massive base while offering IgA synergy for holistic immune defense.

Business Model

B2B Sales: Direct partnerships with hospitals (51.6% channel dominance).

Competitive Pricing: $40K/patient/year (20% below current market rates).

Unit Economics: High margins (60%+) via scalable recombinant production.

Customer Value: LTV of $200k+ with high retention rates (5+ years).

Go-to-Market Strategy

Phase 1 targets US & EU markets via Key Opinion Leader (KOL) endorsements in PID clinics. Phase 2 expands to the rapidly growing Asia-Pacific region. Our digital strategy leverages online pharmacy channels (growing at 10.4% CAGR) to reach chronic patients directly.

Financial Projections (USD Millions)

We project reaching $800M in revenue by Year 5 with a 35% EBITDA margin. Break-even occurs in Year 2, with significant acceleration driven by market expansion and IP licensing.

Investment Ask: $20M Series A

Funding Phase 2 Trials & Global Launch. Projected 10x ROI by 2030.